Daré Bioscience Q2 FY26 net loss narrows to $2.98 million; revenue rises to $187,546

PUBT · 1d ago
Daré Bioscience Q2 FY26 net loss narrows to $2.98 million; revenue rises to $187,546
  • Daré Bioscience posted a Q2 net loss of $2.98 million, narrowing from $4.02 million a year earlier; loss per share improved to $0.20.
  • Revenue rose to $187,546 from negative $21,172, reflecting Gates Foundation R&D services, partly offset by lower non-cash XACIATO royalty revenue.
  • Operating loss narrowed to $2.97 million from $3.83 million, while R&D expense fell to $241,966 from $1.43 million on higher contra-R&D offsets.
  • Cash and cash equivalents totaled $12.62 million at June 30, 2026, down from $24.71 million at Dec. 31, 2025.
  • Flora Sync LF5 began generating revenue in July; DARE to PLAY Sildenafil Cream dispensing and initial revenue are expected to start in Q3 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Dare Bioscience Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608131601PRIMZONEFULLFEED9809198) on August 13, 2026, and is solely responsible for the information contained therein.